Literature DB >> 17984958

A prospective assessment of androgen levels in patients with autistic spectrum disorders: biochemical underpinnings and suggested therapies.

David A Geier1, Mark R Geier.   

Abstract

Impairments in social relatedness and communication, repetitive behaviors, abnormal movement patterns, and sensory dysfunction characterize autism spectrum disorders (ASDs). Seventy consecutive patients with an ASD diagnosis (DSM-IV criteria, >/= 6 years-old) who presented to the Genetic Centers of America for outpatient genetic/developmental evaluations from 2005-2007 were examined. Patients were evaluated using CLIA-approved Laboratory Cooperation of America (LabCorp) testing for: serum testosterone, serum free testosterone, % free testosterone, serum/plasma dehydroepiandrosterone (DHEA), androstendione, and follicle-stimulating hormone (FSH). Morning blood samples collected following an overnight fast, compared to the pertinent reference means, showed significantly increased relative mean levels for: serum testosterone (158%), serum free testosterone (214%), percent free testosterone (121%), DHEA (192%), and androstenedione (173%). By contrast, compared to the pertinent reference mean, the relative mean level of FSH (51%) was significantly decreased. Additionally, at least one of the androgen attributes examined exceeded its recognized laboratory age- and sex-specific reference range in 81.4% (57 of 70) of the patients examined. With respect to their age- and sex-specific reference ranges, females had significantly higher overall mean relative testosterone and relative free testosterone levels than males. Increased androgens in patients diagnosed with ASDs may involve cyclical interactions between the androgen and the transsulfuration pathways, particularly following mercury exposure. A review of therapies that have significantly improved clinical outcomes in ASD patients indicates they share commonality in helping lower androgens. Thus, androgens should be routinely clinically measured in patients with an ASD diagnosis and appropriate androgen-lowering therapies considered for those who have significantly elevated levels.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17984958

Source DB:  PubMed          Journal:  Neuro Endocrinol Lett        ISSN: 0172-780X            Impact factor:   0.765


  28 in total

1.  Altered peripheral BDNF mRNA expression and BDNF protein concentrations in blood of children and adolescents with autism spectrum disorder.

Authors:  Regina Taurines; Monica Segura; Martin Schecklmann; Laura Albantakis; Edna Grünblatt; Susanne Walitza; Thomas Jans; Benjamin Lyttwin; Michael Haberhausen; Frank M Theisen; Berthold Martin; Wolfgang Briegel; Johannes Thome; Christina Schwenck; Marcel Romanos; Manfred Gerlach
Journal:  J Neural Transm (Vienna)       Date:  2014-02-06       Impact factor: 3.575

Review 2.  Potential Sex Differences Relative to Autism Spectrum Disorder and Metals.

Authors:  Aisha S Dickerson; Ran S Rotem; MacKinsey A Christian; Vy T Nguyen; Aaron J Specht
Journal:  Curr Environ Health Rep       Date:  2017-12

3.  Sex differences in autism: a resting-state fMRI investigation of functional brain connectivity in males and females.

Authors:  Kaat Alaerts; Stephan P Swinnen; Nicole Wenderoth
Journal:  Soc Cogn Affect Neurosci       Date:  2016-03-17       Impact factor: 3.436

Review 4.  Sex Differences in Autism Spectrum Disorder: a Review.

Authors:  Sarah L Ferri; Ted Abel; Edward S Brodkin
Journal:  Curr Psychiatry Rep       Date:  2018-03-05       Impact factor: 5.285

5.  A more efficient conditional mouse model of Dravet syndrome: Implications for epigenetic selection and sex-dependent behaviors.

Authors:  Aaron D Williams; Franck Kalume; Ruth E Westenbroek; William A Catterall
Journal:  J Neurosci Methods       Date:  2019-06-29       Impact factor: 2.390

Review 6.  Diagnostic and Severity-Tracking Biomarkers for Autism Spectrum Disorder.

Authors:  Geir Bjørklund; Nagwa A Meguid; Afaf El-Ansary; Mona A El-Bana; Maryam Dadar; Jan Aaseth; Maha Hemimi; Joško Osredkar; Salvatore Chirumbolo
Journal:  J Mol Neurosci       Date:  2018-10-24       Impact factor: 3.444

7.  Gonadotropin-releasing hormone agonist against severe aggression in autism.

Authors:  Robin M F van der Weiden; Frans M Helmerhorst; Tomas Eriksson
Journal:  BMJ Case Rep       Date:  2016-09-21

8.  A prospective study of transsulfuration biomarkers in autistic disorders.

Authors:  David A Geier; Janet K Kern; Carolyn R Garver; James B Adams; Tapan Audhya; Mark R Geier
Journal:  Neurochem Res       Date:  2008-07-09       Impact factor: 3.996

Review 9.  Sex differences in autism spectrum disorders.

Authors:  Donna M Werling; Daniel H Geschwind
Journal:  Curr Opin Neurol       Date:  2013-04       Impact factor: 5.710

10.  Androgen influence on prefrontal dopamine systems in adult male rats: localization of cognate intracellular receptors in medial prefrontal projections to the ventral tegmental area and effects of gonadectomy and hormone replacement on glutamate-stimulated extracellular dopamine level.

Authors:  T Aubele; M F Kritzer
Journal:  Cereb Cortex       Date:  2011-09-22       Impact factor: 5.357

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.